Literature DB >> 10751030

Application of a biomagnetic measurement system (BMS) to the evaluation of gastrointestinal transit of intestinal pressure-controlled colon delivery capsules (PCDCs) in human subjects.

Z Hu1, S Mawatari, N Shibata, K Takada, H Yoshikawa, A Arakawa, Y Yosida.   

Abstract

PURPOSE: For determination of the transit time through various parts of the gastrointestinal (GI) tract, we developed a method that provides the location of disintegration and drug release. This method involves GI magnetomarkergraphy (GIMG) using a 129-channel Shimadzu vector biomagnetic measurement system (BMS).
METHODS: To magnetically label the pressure-controlled colon delivery capsule (PCDC) containing 75.0 +/- 0.5 mg of caffeine as a tracer drug, small capsule caps containing 90 mg of ferric oxide powdered magnetite (Fe2O3) were attached to PCDCs. After orally administration to fasted human volunteers, saliva samples were collected hourly and salivary caffeine concentration was measured. At the same time, locations of the magnetic PCDC were detected by BMS just after the PCDCs were magnetized with the coils of a magnetic resonance imaging (MRI) system. The magnetic field distributions were analyzed and the estimated positions were shown on the MRI picture of the same subject's abdominal structure.
RESULTS: We magnetized PCDC with permanent magnets or an electromagnet before ingestion and the estimated locations of PCDC in the GI tract exhibited high estimation error. In order to increase the precision of estimated localization of PCDCs, PCDCs were magnetized within the coils of the MRI. As a result, these PCDCs had strong magnetic dipoles that were parallel to the sensor unit of BMS in every measurement, and therefore the spatial resolution of the PCDC's two-dimensional positions in the organs of the GI tract was within a range of several millimeters.
CONCLUSIONS: GIMG is a powerful tool for the study of colon delivery efficiencies of PCDCs. The main advantage of GIMG is the capability to obtain even more detailed knowledge of the behavior and fate of solid pharmaceutical formulations during GI passage.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10751030     DOI: 10.1023/a:1007561129221

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  17 in total

Review 1.  Delivery systems for biopharmaceuticals.

Authors:  S S Davis
Journal:  J Pharm Pharmacol       Date:  1992-02       Impact factor: 3.765

2.  DETECTION OF THE MAGNETIC FIELD OF THE HEART.

Authors:  G BAULE; R MCFEE
Journal:  Am Heart J       Date:  1963-07       Impact factor: 4.749

3.  Scintigraphic evaluation of a new capsule-type colon specific drug delivery system in healthy volunteers.

Authors:  T Ishibashi; G R Pitcairn; H Yoshino; M Mizobe; I R Wilding
Journal:  J Pharm Sci       Date:  1998-05       Impact factor: 3.534

Review 4.  Immunosuppressive drugs in inflammatory bowel disease. A review of their mechanisms of efficacy and place in therapy.

Authors:  A B Hawthorne; C J Hawkey
Journal:  Drugs       Date:  1989-08       Impact factor: 9.546

Review 5.  Intestinal absorption of proteins and macromolecules and the immunological response.

Authors:  D T O'Hagan; K J Palin; S S Davis
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  1988       Impact factor: 4.889

6.  Magnetoencephalography: evidence of magnetic fields produced by alpha-rhythm currents.

Authors:  D Cohen
Journal:  Science       Date:  1968-08-23       Impact factor: 47.728

7.  Relationship of the magnetoencephalogram to abnormal activity in the electroencephalogram.

Authors:  J R Hughes; J Cohen; C I Mayman; M L Scholl; D E Hendrix
Journal:  J Neurol       Date:  1977-12-13       Impact factor: 4.849

8.  Application of a colon delivery capsule to 5-aminosalicylic acid and evaluation of the pharmacokinetic profile after oral administration to beagle dogs.

Authors:  T Takaya; K Sawada; H Suzuki; A Funaoka; K Matsuda; K Takada
Journal:  J Drug Target       Date:  1997       Impact factor: 5.121

9.  Evaluation of intestinal pressure-controlled colon delivery capsule containing caffeine as a model drug in human volunteers.

Authors:  M Muraoka; Z Hu; T Shimokawa; S Sekino; R Kurogoshi; Y Kuboi; Y Yoshikawa; K Takada
Journal:  J Control Release       Date:  1998-03-02       Impact factor: 9.776

10.  Development of a colonic release capsule dosage form and the absorption of insulin.

Authors:  M E Kraeling; W A Ritschel
Journal:  Methods Find Exp Clin Pharmacol       Date:  1992-04
View more
  6 in total

Review 1.  Nanomedicine in GI.

Authors:  Hamed Laroui; David S Wilson; Guillaume Dalmasso; Khalid Salaita; Niren Murthy; Shanthi V Sitaraman; Didier Merlin
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-12-09       Impact factor: 4.052

Review 2.  Advances in colonic drug delivery.

Authors:  Abdul W Basit
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Pharmacokinetics and efficacy of orally administered polymeric chloroquine as macromolecular drug in the treatment of inflammatory bowel disease.

Authors:  Shrey Kanvinde; Yashpal Singh Chhonker; Rizwan Ahmad; Fei Yu; Richard Sleightholm; Weimin Tang; Lee Jaramillo; Yi Chen; Yuri Sheinin; Jing Li; Daryl J Murry; Amar B Singh; David Oupický
Journal:  Acta Biomater       Date:  2018-10-17       Impact factor: 8.947

Review 4.  Advances in Oral Drug Delivery for Regional Targeting in the Gastrointestinal Tract - Influence of Physiological, Pathophysiological and Pharmaceutical Factors.

Authors:  Susan Hua
Journal:  Front Pharmacol       Date:  2020-04-28       Impact factor: 5.810

Review 5.  Current Advances in Chitosan Nanoparticles Based Oral Drug Delivery for Colorectal Cancer Treatment.

Authors:  Hazem Choukaife; Salma Seyam; Batoul Alallam; Abd Almonem Doolaanea; Mulham Alfatama
Journal:  Int J Nanomedicine       Date:  2022-09-07

Review 6.  New Insights of Oral Colonic Drug Delivery Systems for Inflammatory Bowel Disease Therapy.

Authors:  Adrian H Teruel; Isabel Gonzalez-Alvarez; Marival Bermejo; Virginia Merino; Maria Dolores Marcos; Felix Sancenon; Marta Gonzalez-Alvarez; Ramon Martinez-Mañez
Journal:  Int J Mol Sci       Date:  2020-09-05       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.